1 to 3 capsules with meals daily or as directed by physician.

Acetyl-L-Carnitine hydrochloride 500mg (preferred, stable form).

Gelatin Capsule (Bovine), Cellulose, water, magnesium stearate and silica.

Acetyl-L-carnitine plays a key role in maintaining acetylcholine level and neuroprotective function during aging, as many well-designed human and animal studies have shown consistently. Acetyl-L-carnitine is a naturally occurring compound that supports normal brain and nerve function during aging through various mechanisms. These include its actions on acetylcholine synthesis, cellular membrane stability. nerve growth factor production, and cerebral blood flow.

Acetyl-L-Carnitine is a potent form of carnitine used by the brain and nervous system. The amino acid L-Carnitine and its acetylated derivative, Acetyl-L-Carnitine (ALC), assist transport of fatty acids into cellular mitochondria for energy production. The acetyl group that is part of acetyl-L-carnitine contributes to the production of the neurotransmitter acetylcholine, which is required for mental function. Both nutrients are found naturally in our diets. While most L-Carnitine research has focused on its role in cardiac and skeletal muscle, ALC research has concentrated on its role in brain and nervous system function during aging. ALC can serve as a metabolic source of acetylcholine, a neurotransmitter involved in brain function. And, unlike L-carnitine, ALC has protective antioxidant benefit for cell membranes. ALC appears to be absorbed intact and is capable of crossing the blood-brain barrier.

Not recommended if you're pregnant or nursing. Keep out of reach of children.

In an Italy study published 2002, 333 patients with diabetic peripheral neuropathy were randomized in a double-blinded, placebo-controlled fashion. Half of the patients received initial doses of 1000 mg daily of intramuscular ALC for 10 days followed by 2000 mg a day for the remainder of the year. At the end of the study, those patients treated with ALC showed a statistically significant improvement in nerve conduction responsiveness compared to placebo. In addition, after twelve months of treatment the ALC group had a statistically significant reduction of pain by 39% compared to 8% in the placebo group.

1. Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4.

2. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-41.

3. Cucinotta D, Passeri M, Ventura S, et al. Multicenter clinical placebo-controlled study with acetyl-L-carnitine (LAC) in the treatment of mildly demented elderly patients. Drug Development Res 1988;14:213-6.

4. Sorbi S, Forleo P, Fani C, Piacentini S. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin Neuropharmacol 2000;23:114-8.

5. No authors listed. Acetyl-L-Carnitine. Altern Med Rev 1999;4:438-41 [review].

6. Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-11.

7. Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-47.

This is a statement of nutritional support. This statement has not been evaluated by the FDA. This product is not intended to medically diagnose, treat, cure, or prevent any disease. Always consult your health care provider before using any supplement.